|
1
|
Havre PA, Abe M, Urasaki Y, Ohnuma K,
Morimoto C and Dang NH: The role of CD26/dipeptidyl peptidase IV in
cancer. Front Biosci. 13:1634–1645. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pro B and Dang NH: CD26/dipeptidyl
peptidase IV and its role in cancer. Histol Histopathol.
19:1345–1351. 2004.PubMed/NCBI
|
|
3
|
Beckenkamp A, Davies S, Willig JB and
Buffon A: DPPIV/CD26: A tumor suppressor or a marker of malignancy?
Tumour Biol. 37:7059–7073. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Javidroozi M, Zucker S and Chen WT: Plasma
seprase and DPP4 levels as markers of disease and prognosis in
cancer. Dis Markers. 32:309–320. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Angevin E, Isambert N, Trillet-Lenoir V,
You B, Alexandre J, Zalcman G, Vielh P, Farace F, Valleix F, Podoll
T, et al: First-in-human phase 1 of YS110, a monoclonal antibody
directed against CD26 in advanced CD26-expressing cancers. Br J
Cancer. 116:1126–1134. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ho L, Aytac U, Stephens LC, Ohnuma K,
Mills GB, McKee KS, Neumann C, LaPushin R, Cabanillas F, Abbruzzese
JL, et al: In vitro and in vivo antitumor effect of the anti-CD26
monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell
lymphoma Karpas 299. Clin Cancer Res. 7:2031–2040. 2001.PubMed/NCBI
|
|
7
|
Femia AP, Raimondi L, Maglieri G, Lodovici
M, Mannucci E and Caderni G: Long-term treatment with Sitagliptin,
a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis
and reactive oxygen species in 1,2-dimethylhydrazine-induced rats.
Int J Cancer. 133:2498–2503. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tang Z, Li J, Shen Q, Feng J, Liu H, Wang
W, Xu L, Shi G, Ye X, Ge M, et al: Contribution of upregulated
dipeptidyl peptidase 9 (DPP9) in promoting tumoregenicity,
metastasis and the prediction of poor prognosis in non-small cell
lung cancer (NSCLC). Int J Cancer. 140:1620–1632. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gonzalez-Gronow M, Grenett HE, Weber MR,
Gawdi G and Pizzo SV: Interaction of plasminogen with dipeptidyl
peptidase IV initiates a signal transduction mechanism which
regulates expression of matrix metalloproteinase-9 by prostate
cancer cells. Biochem J. 355:397–407. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Havre PA, Dang LH, Ohnuma K, Iwata S,
Morimoto C and Dang NH: CD26 expression on T-anaplastic large cell
lymphoma (ALCL) line Karpas 299 is associated with increased
expression of versican and MT1-MMP and enhanced adhesion. BMC
Cancer. 13:5172013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ghersi G, Zhao Q, Salamone M, Yeh Y,
Zucker S and Chen WT: The protease complex consisting of dipeptidyl
peptidase IV and seprase plays a role in the migration and invasion
of human endothelial cells in collagenous matrices. Cancer Res.
66:4652–4661. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kraman M, Bambrough PJ, Arnold JN, Roberts
EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA and Fearon DT:
Suppression of antitumor immunity by stromal cells expressing
fibroblast activation protein-alpha. Science. 330:827–830. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liao Y, Ni Y, He R, Liu W and Du J:
Clinical implications of fibroblast activation protein-α in
non-small cell lung cancer after curative resection: A new
predictor for prognosis. J Cancer Res Clin Oncol. 139:1523–1528.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dang NH, Torimoto Y, Schlossman SF and
Morimoto C: Human CD4 helper T cell activation: Functional
involvement of two distinct collagen receptors, 1F7 and VLA
integrin family. J Exp Med. 172:649–652. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dang DT, Chun SY, Burkitt K, Abe M, Chen
S, Havre P, Mabjeesh NJ, Heath EI, Vogelzang NJ, Cruz-Correa M, et
al: Hypoxia-inducible factor-1 target genes as indicators of tumor
vessel response to vascular endothelial growth factor inhibition.
Cancer Res. 68:1872–1880. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ohnuma K, Hatano R and Morimoto C: DPP4 in
anti-tumor immunity: Going beyond the enzyme. Nat Immunol.
16:791–792. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Janssens R, Mortier A, Boff D, Ruytinx P,
Gouwy M, Vantilt B, Larsen O, Daugvilaite V, Rosenkilde MM,
Parmentier M, et al: Truncation of CXCL12 by CD26 reduces its CXC
chemokine receptor 4- and atypical chemokine receptor 3-dependent
activity on endothelial cells and lymphocytes. Biochem Pharmacol.
132:92–101. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
da Silva Barreira R, Laird ME, Yatim N,
Fiette L, Ingersoll MA and Albert ML: Dipeptidylpeptidase 4
inhibition enhances lymphocyte trafficking, improving both
naturally occurring tumor immunity and immunotherapy. Nat Immunol.
16:850–858. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Beckenkamp A, Willig JB, Santana DB,
Nascimento J, Paccez JD, Zerbini LF, Bruno AN, Pilger DA, Wink MR
and Buffon A: Differential expression and enzymatic activity of
DPPIV/CD26 affects migration ability of cervical carcinoma cells.
PLoS One. 10:e01343052015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jang JH, Baerts L, Waumans Y, De Meester
I, Yamada Y, Limani P, Gil-Bazo I, Weder W and Jungraithmayr W:
Suppression of lung metastases by the CD26/DPP4 inhibitor
Vildagliptin in mice. Clin Exp Metastasis. 32:677–687. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lam CS, Cheung AH, Wong SK, Wan TM, Ng L,
Chow AK, Cheng NS, Pak RC, Li HS, Man JH, et al: Prognostic
significance of CD26 in patients with colorectal cancer. PLoS One.
9:e985822014. View Article : Google Scholar : PubMed/NCBI
|
